Global pharmaceutical company Lupin Limited has announced a license and supply agreement with SteinCares, a leading specialty healthcare company in Latin America. The partnership covers the commercialization of Lupin’s biosimilar ranibizumab across Latin America, excluding Mexico and Argentina.
As part of the agreement, SteinCares will oversee all regulatory filings, product registrations, and commercial operations in the region. Lupin will retain responsibility for the manufacturing of the biosimilar.
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment designed to inhibit vascular endothelial growth factor A (VEGF-A), a key driver in several retinal diseases. It is approved for the treatment of:
Dr. Cyrus Karkaria, President – Biotechnology, Lupin, emphasized the company's commitment to innovation and access:
“Our partnership with SteinCares underscores our commitment to providing innovative, high-quality healthcare solutions to patients in LATAM. Our intent is to transform the landscape of retinal care in Latin America, ensuring access to advanced therapies that improve the quality of life of patients.”
Sebastián Katz, Chief Strategy Officer, SteinCares, highlighted the strategic value of the deal:
“This partnership with Lupin strengthens our portfolio and further reinforces SteinCares’ position as a biosimilar powerhouse in Latin America. We have consistently been first to market products from highly regulated markets across several countries in the region. Our presence has translated into significant cost savings for healthcare institutions, driven by decades of experience and a deep understanding of Latin America's healthcare landscape.”
Headquartered in Mumbai, India, Lupin is a global leader in pharmaceuticals with a presence in over 100 markets. The company develops and manufactures branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients (APIs).
SteinCares is a prominent name in the commercialization and distribution of specialty healthcare products across Latin America and the Caribbean.
With over 40 years of experience and operations in more than 30 countries, SteinCares bridges the gap between global pharmaceutical innovators and regional healthcare providers, specializing in biosimilars, complex generics, and innovative therapies.